AliveGen USA Inc. (AliveGen), a clinical stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALG-801 for the ...
PAH is a rare condition in children, but is often fatal if left untreated, and protocols for pediatric patients have not been ...
In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.
A Mendelian analysis supports the idea that hyperuricemia may be an important risk factor for pulmonary arterial hypertension ...
A new treatment, Sotatercept, for pulmonary arterial hypertension (PAH) has recently been approved by the MHRA ...
People with pulmonary arterial hypertension (PAH) experience a high disease burden and their quality of life worsens as their ...
Up to 50% of patients with pulmonary embolism (PE) experience hemodynamic instability and approximately 70% of patients who die of PE experience an accelerated cascade of symptoms within the first ...
Lung diseases such as ALI, asthma, pulmonary fibrosis, pulmonary hypertension, COPD ... ROS formation and endogenous antioxidant defense is important in inhibiting pathogenesis. The experimental ...
The pulmonary vasculature is the exclusive target of disease in PPH, although its pathogenesis remains ... PPH associated with pulmonary arterial hypertension include collagen vascular disease ...
Your inner ear is sensitive to changes in pressure and blood flow. If you live with hypertension, you may notice emerging challenges with hearing, tinnitus, vertigo, or a sensation of “fullness ...
Background: Pulmonary arterial hypertension (PAH) is characterized by elevated pulmonary artery pressure and vascular resistance, leading to systemic venous hypertension and potential right heart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback